XM does not provide services to residents of the United States of America.

XM does not provide services to residents of the United States of America.
A
A

Abbott

News

Reuters - 4 days ago

What to Watch in the Week Ahead and on Monday, July 15

What to Watch in the Week Ahead and on Monday, July 15 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT ON MONDAY Federal Reserve Chair Jerome Powell is set to participate in a conversation hosted by the Economic Club of Washington.
A
A
C
G
H
H
N
N
F
U
C
M
Reuters - 5 days ago

AbbVie asks US Supreme Court to weigh protections for attorney records

AbbVie asks US Supreme Court to weigh protections for attorney records By Mike Scarcella July 11 (Reuters) - Pharmaceutical company AbbVie ABBV.N has asked the U.S. Supreme Court to take up its fight to protect corporate records, warning that a lower court ruling threatens to erode the shield that keeps most attorney communications off-limits from a company's courtroom opponents.
A
Reuters - 6 days ago

First trial against Abbott over premature infant formula kicks off in Missouri

First trial against Abbott over premature infant formula kicks off in Missouri By Brendan Pierson July 9 (Reuters) - The first trial against Similac baby formula maker Abbott ABT.N over claims that its formula for preterm infants used in neonatal intensive care units causes a potentially deadly bowel disease got underway with opening statements on Tuesday, as a lawyer for a mother suing the company urged jurors to hold it liable for her child's lifelong injuries.
A
B
Reuters - 1 week ago

Abbott faces trial over claims that preterm infant formula caused dangerous disease

Abbott faces trial over claims that preterm infant formula caused dangerous disease By Brendan Pierson July 8 (Reuters) - Similac baby formula maker Abbott ABT.N is expected to face a trial on Monday over claims that its formula for preterm infants used in neonatal intensive care units causes a potentially deadly bowel disease, the second trial out of hundreds of similar lawsuits in the United States.
A
B
Reuters - 2 weeks ago

Bain-backed Emcure Pharma's $234 mln India IPO draws $11 bln in bids

Bain-backed Emcure Pharma's $234 mln India IPO draws $11 bln in bids By VarunVyas Hebbalalu and Kashish Tandon BENGALURU, July 5 (Reuters) - India's Emcure Pharmaceuticals EMCU.NS drew strong interest for its $234 million initial public offering (IPO) as investors bet on its slate of women's healthcare and HIV treatments to drive growth in a high-margin market.
A
G
Reuters - 3 weeks ago

FDA Says Abbott Medical Issues Correction For Heartmate LVAS System Monitor Due To Screen Issues That May Cause Unintentional Pump Stop

BRIEF-FDA Says Abbott Medical Issues Correction For Heartmate LVAS System Monitor Due To Screen Issues That May Cause Unintentional Pump Stop June 28 (Reuters) - FDA: FDA: ABBOTT MEDICAL ISSUES CORRECTION FOR HEARTMATE LVAS SYSTEM MONITOR DUE TO SCREEN ISSUES THAT MAY CAUSE UNINTENTIONAL PUMP STOP FDA: THERE HAVE BEEN 14 REPORTED INJURIES, NO REPOR
A
Reuters - 1 month ago

Olympic athletes turn to diabetes tech in pursuit of medals

FOCUS-Olympic athletes turn to diabetes tech in pursuit of medals Repeats to wider addresses, no changes to text By Ludwig Burger June 10 (Reuters) - Olympians including Dutch marathon runner Abdi Nageeye are using a new tool they hope will boost their medal chances this summer: tiny monitors that attach to the skin to track blood glucose levels. Continuous glucose monitors or CGMs were developed for use by diabetes patients but their makers, led by Abbott ABT.N and Dexcom DXCM.O , also spy oppo
A
Reuters - 1 month ago

Olympic athletes turn to diabetes tech in pursuit of medals

FOCUS-Olympic athletes turn to diabetes tech in pursuit of medals Updates to add U.S. approval of Abbott's prescription-free CGMs in paragraphs 10, 11 By Ludwig Burger June 10 (Reuters) - Olympians including Dutch marathon runner Abdi Nageeye are using a new tool they hope will boost their medal chances this summer: tiny monitors that attach to the skin to track blood glucose levels.
A
Reuters - 1 month ago

Abbott secures FDA clearance for two over-the-counter glucose monitors

UPDATE 3-Abbott secures FDA clearance for two over-the-counter glucose monitors Adds analyst comment in paragraphs 4 and 8, shares in paragraph 10 By Pratik Jain and Sriparna Roy June 10 (Reuters) - Abbott Laboratories ABT.N said on Monday the U.S. health regulator had cleared the company's two new over-the-counter glucose monitoring devices, expanding its presence in a fast-growing, multi-billion-dollar market.
A
Reuters - 1 month ago

US FDA clears Abbott's continuous glucose monitors for over-the-counter use

US FDA clears Abbott's continuous glucose monitors for over-the-counter use June 10 (Reuters) - Abbott ABT.N said on Monday that the U.S. Food and Drug Administration has cleared its two continuous glucose monitoring systems for over-the-counter use. Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber
A
Reuters - 1 month ago

Olympic athletes turn to diabetes tech in pursuit of medals

FOCUS-Olympic athletes turn to diabetes tech in pursuit of medals By Ludwig Burger June 10 (Reuters) - Olympians including Dutch marathon runner Abdi Nageeye are using a new tool they hope will boost their medal chances this summer: tiny monitors that attach to the skin to track blood glucose levels. Continuous glucose monitors or CGMs, were developed for use by diabetes patients but their makers, led by Abbott ABT.N and Dexcom DXCM.O , also spy opportunities in sports and wellness.
A
Reuters - 1 month ago

Why are top athletes using diabetes tech in pursuit of medals?

FACTBOX-Why are top athletes using diabetes tech in pursuit of medals? June 10 (Reuters) - Some Olympic athletes are using a new tool they hope will boost their medal chances this summer: tiny monitors that attach to the skin to track blood glucose levels. The market for continuous glucose monitors (CGMs), developed to help diabetes patients fine-tune their insulin shots, is already worth billions of dollars per year.
A
Reuters - 1 month ago

U.S. STOCKS Semtech, United Rentals, Toro

BUZZ-U.S. STOCKS ON THE MOVE-Semtech, United Rentals, Toro Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes dropped on Friday after a much stronger-than-expected employment report signaled that the labor market remains robust, dimming hopes of a September start to policy easing by the U.S.
A
G
J
M
N
L
U
U
A
L
S
C
U
Reuters - 1 month ago

Abbott Laboratories loses bid to halt Glucerna class action

Abbott Laboratories loses bid to halt Glucerna class action By Diana Novak Jones June 6 (Reuters) - Litigation claiming that Abbott Laboratories is marketing Glucerna shakes and nutritional powders with harmful ingredients can move forward, a California federal judge said Wednesday. U.S. District Judge P. Casey Pitts in San Jose largely rejected Abbott’s motion to dismiss the proposed class action, ruling that the consumers had provided enough evidence at this stage to support their claims tha
A
Reuters - 2 months ago

U.S. Connectone Bancorp, Hormel Foods, UMB Financial

U.S. RESEARCH ROUNDUP-Connectone Bancorp, Hormel Foods, UMB Financial May 31 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Connectone Bancorp, Hormel Foods and UMB Financial, on Friday. HIGHLIGHTS * Connectone Bancorp Inc CNOB.O : KBW cuts to market perform from outperform * Hancock Whitney Corp HWC.O : KBW raises to outperform from market perform * Hormel Foods Corp HRL.N : JP Morgan raises to neutral from underwe
A
A
C
M
M
N
P
S
A
U
A
B
D
E
E
X
M
Reuters - 2 months ago

U.S. FDA set to reorganize its food division starting October

U.S. FDA set to reorganize its food division starting October May 30 (Reuters) - The U.S. Food and Drug Administration(FDA) said on Thursday it plans to restructure its food division starting in October helping it to oversee human food supply chains and agricultural products more efficiently. The regulatory body had come under fire over its slow response to the infant formula shortage in 2022. WHY IT'S IMPORTANT The FDA said the reorganization will enable it to be more efficient and agile while
A
Reuters - 2 months ago

Medtronic's weaker-than-expected outlook clouds quarterly results beat

UPDATE 4-Medtronic's weaker-than-expected outlook clouds quarterly results beat Adds CFO comments in paragraphs 5 and 10, graphic By Pratik Jain and Christy Santhosh May 23 (Reuters) - Medtronic MDT.N beat estimates for fourth-quarter revenue and profit on Thursday, helped by robust sales of its medical devices, but shares declined more than 3% after its forecast for the current quarter fell short of Wall Street expectations.
A
Reuters - 2 months ago

U.S. Ameriprise Financial, Dell Technologies, Stryker

U.S. RESEARCH ROUNDUP-Ameriprise Financial, Dell Technologies, Stryker May 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Ameriprise Financial, Dell Technologies and Stryker, on Wednesday. HIGHLIGHTS * Ameriprise Financial Inc AMP.N : Jefferies raises target price to $500 from $487 * Bio-Techne Corp TECH.O : Citigroup cuts to neutral from buy * Dell Technologies Inc DELL.N : Raymond James raises target price to $
A
A
C
C
U
D
G
A
A
D
I
K
L
Reuters - 2 months ago

GlaxoSmithKline Pharma India posts higher Q4 adjusted profit on strong sales

GlaxoSmithKline Pharma India posts higher Q4 adjusted profit on strong sales BENGALURU, May 17 (Reuters) - Drugmaker GlaxoSmithKline Pharma India GLAX.NS reported a 49% rise in fourth-quarter adjusted profit on Friday , as strong demand for its generic medicines offset the impact of the government's ongoing price curbs on its key drugs. The company reported consolidated profit before exceptional items and taxes of 2.68 billion rupees ($32.1 million) for the quarter ended March 31, compared to 1.
A
G
Reuters - 2 months ago

Indian shares see worst week since mid-March as volatility, foreign selling weighs

INDIA STOCKS-Indian shares see worst week since mid-March as volatility, foreign selling weighs Updates with closing levels at 3:30 p.m. IST By Bharath Rajeswaran and Hritam Mukherjee BENGALURU, May 10 (Reuters) - Indian shares ended higher on Friday, but logged their worst week in eight as concerns over the outcome of ongoing national elections and selling by foreign investors weighed on sentiment .
A

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.